YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
New Nemluvio® (nemolizumab) post-hoc data from the ARCADIA long-term extension (LTE) study showed the majority of Week 16 responders maintained deep and lasting skin lesion and itch response for up to three years1 Additional long-term data…
Galderma celebrates the 30th anniversary of Restylane, its pioneering range of hyaluronic acid (HA) injectables that established the category as the first to market1 With three decades of innovation across technology, packaging, and treatm…
New three-year ARCADIA long-term extension data demonstrate that Nemluvio is well-tolerated and associated with sustained and continuous improvements in skin lesions, itch, sleep disturbance and quality of life in adults and adolescents wi…
Galderma will present 19 abstracts, including two oral presentations, at the 2026 EADV Congress, with new data on skin diseases, skin longevity and real-world patient experiences New analyses from the Nemluvio® (nemolizumab) clinical devel…
Galderma Group (SWX:GALD) has just raised its full-year 2026 net sales growth guidance to a range of 19% to 21% at constant currency, after reporting 24.6% year-on-year net sales growth in the first half. Galderma Group's recent guidance l…
ZUG, Switzerland, September 21, 2026--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today begins trading as a constituent of the Swiss Market Index (SMI), Switzerland's leading blue chip equity benchmark…
Positive topline results showed that Restylane Volyme (known as Restylane Contour in the U.S.) was highly effective in the correction of moderate-to-severe temple hollowing, with high responder rates maintained through Month 121 Restylane…
Galderma has introduced the first-and-only shaper to the hyaluronic acid (HA) market with Restylane Shaype, now approved in the European Union (EU) for chin augmentation1 Restylane Shaype is the firmest HA gel available, powered by new NAS…
IPO Edge hosted a fireside chat with Conexeu Sciences Inc. (Nasdaq: CNXU) President and Chief Executive Officer Miles Harrison, moderated by IPO Edge Editor-in-Chief John Jannarone and Editor-at-Large Jarrett Banks in a video session lasti…
Investing.com -- Morgan Stanley on Thursday upgraded Galderma Group AG to "overweight" from "equal-weight" and raised its price target to 210 Swiss francs from 160 Swiss francs, citing higher growth forecasts for the company's Nemluvio dru…
This article first appeared on GuruFocus. Release Date: July 23, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Galderma Group AG (GDERF) delivered record net sales…
Ad hoc announcement pursuant to Art. 53 LR ZUG, Switzerland, July 23, 2026--(BUSINESS WIRE)--Galderma Group AG (SIX: GALD), the pure-play dermatology category leader, today announced its financial results for the first half of 2026. Net sa…
Galderma launches Alastin, its premium regenerative skincare brand into Japan, Singapore, South Korea and Taiwan The Japan and Asia Pacific (JPAC) region is among the fastest‑growing markets globally for medical aesthetics and dermatologic…
Skin quality assessment scale - Dr. Metelitsa World's most extensive skin quality profiling survey of more than 11,000 people across Europe, Asia, and the Americas finds that nine out of ten people are affected by skin quality concerns, wi…
Issued on behalf of Conexeu Sciences Inc. Conexeu Sciences Inc. (NASDAQ: CNXU) opened a new research and development facility at adMare BioInnovations’ M4 Innovation Centre, expanding the home of its CXU™ regenerative tissue platform, a si…
Investing.com -- Swiss dermatology companyGalderma Group AG (SIX:GALD) fell nearly 6% on Wednesday after the U.S. Food and Drug Administration declined to approve its wrinkle treatment RelabotulinumtoxinA, delaying the product's planned en…
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 2…
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Eledon Pharmaceuticals, Inc. (ELDN) been one of those stocks this year? A quick glance at the compan…
Results from Galderma’s global survey showed that performance is the top priority for healthcare professionals (HCPs), with long-lasting results, pure, highly active formulations, and fast onset cited as the leading criteria for recommendi…
The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne suf…
Galderma Group AG - Unsponsored ADR (GALDY) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock pric…
As European markets face headwinds with the pan-European STOXX Europe 600 Index down 2.54% and major indices like Germany’s DAX and France’s CAC 40 seeing declines, investors are increasingly focused on finding opportunities amidst the bro…
As European markets face heightened geopolitical risks and economic uncertainty, with the STOXX Europe 600 Index down 2.54% for the week, investors are increasingly looking for opportunities in undervalued stocks that may offer resilience…
(RTTNews) - Galderma Group AG (GDERF, GALD.SW), a Swiss skincare firm, on Thursday reported sales growth for its first quarter, with improved performance in all segments. Further, Galderma confirmed its 2026 guidance of 17 percent to 20 pe…
Ad hoc announcement pursuant to Art. 53 LR ZUG, Switzerland, April 23, 2026--(BUSINESS WIRE)--Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first quarter of 2026. Str…
ZUG, Switzerland, April 22, 2026--(BUSINESS WIRE)--Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, announced that shareholders approved all proposals put forward by the Board of Directors at its Annual General Meet…
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Galderma Group stock snapshot after recent performance Galderma Group (SWX:GALD) has attracted atte…
The Board of Directors proposes a dividend of 0.35 CHF per registered share Harry Kirsch proposed as new independent member of the Board of Directors Delphine Viguier-Hovasse and Samuel du Retail proposed as two non-independent board membe…
EQT completes final sell-down in Galderma, a global dermatology company delivering science-backed solutions to healthcare professionals, consumers and patients worldwide Under EQT's ownership, Galderma significantly accelerated revenue gro…
(RTTNews) - Galderma Group AG (GALD.SW, GDERF), a Swiss-based, pure-play dermatology company, on Thursday on Wednesday agreed to repurchase 1.6 million shares. The share repurchase is expected to settle on March 13 and will be financed usi…
Ad hoc announcement pursuant to Art. 53 LR ZUG, Switzerland, March 11, 2026--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it has agreed to repurchase 1.6 million shares at a price o…
Cetaphil’s new AM/PM Serums are powered by unique Gallic-AOX Power™ Technology, a patent-pending antioxidant complex clinically designed to sync to your skin’s circadian rhythm and support skin resilience Delivers advanced antioxidant prot…
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Galderma Group (SWX:GALD) is back in focus after reporting record 2025 results, with net sales above US$5b, net income of US$613 mi…
This article first appeared on GuruFocus. Release Date: March 05, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Galderma Group AG (GDERF) reported record net sales…
Ad hoc announcement pursuant to Art. 53 LR ZUG, Switzerland, March 05, 2026--(BUSINESS WIRE)--Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year 2025. Record net…
Restylane syringe NASHA Regulatory authorities in the European Union (EU), the United States (U.S.), and Canada have approved a new state-of-the-art Restylane®syringe for use with a range of Restylane NASHA® lidocaine products in multiple…